Simethicone and N-acetyl cysteine combination as premedication before esophagogastroduodenoscopy: Double-blind randomized controlled trial

Abstract

Background and study aims Esophagogastroduodenoscopy (EGD), the most common method used for diagnosing upper gastrointestinal diseases, is often limited by the presence of foam and mucous. Thus, this study was designed to detect whether the combination of simethicone with N-acetyl cysteine (NAC) as premedication before EGD improves mucosal visualization.

Patients and methods A total of 768 consenting patients were enrolled in this prospective, double-blind, randomized placebo-controlled trial in four groups (A: simethicone + N-acetyl cysteine; B: simethicone alone; C: NAC alone; and D: placebo). After 20 minutes of consuming the corresponding solution, EGD was done and multiple images were obtained from the esophagus, stomach, and duodenum. Based on the various images obtained, the study parameters were calculated. Statistical Analysis Software (SAS) was used to analyze the results using Kruskal-Wallis with the Bonferroni correction method.

Results The study population consisted of 57 % men and the mean age was 44.18 years. Each group was randomized with 192 participants. Group A (combination of simethicone + NAC) premedication had the lowest total mucosal visibility score of 8.31, a significantly lower score for mucous/bubbles obscuring the vision, and less time to complete the procedure. Also, 81 % of the participants in group A did not require flushing to clear the mucous/bubbles. There were no side effects due to this premedication in any of the groups.

Conclusions  Using simethicone and NAC combined for premedication may improve the quality of EGD.

Publication History

Received: 09 July 2019

Accepted after revision: 13 January 2022

Article published online:
13 May 2022

• References

• 1 Park WG, Shaheen NJ, Cohen J. et al. Quality indicators for EGD. Gastrointest Endosc 2015; 81: 17-30
• 2 Veitch AM, Uedo N, Yao K. et al. Optimizing early upper gastrointestinal cancer detection at endoscopy. Nat Rev Gastroenterol Amp Hepatol 2015; 12: 660
• 3 Yao K. The endoscopic diagnosis of early gastric cancer. Ann Gastroenterol Q Publ Hell Soc Gastroenterol 2013; 26: 11-22
• 4 Petersen BT. Quality assurance for endoscopists. Best Pract Res Clin Gastroenterol 2011; 25: 349-360
• 5 Kwan V, Devière J. Endoscopy essentials: preparation, sedation, and surveillance. Endoscopy 2008; 40: 65-70
• 6 Ahsan M, Babaei L, Gholamrezaei A. et al. Simethicone for the preparation before esophagogastroduodenoscopy. Diagn Ther Endosc 2011; 2011: 484532
• 7 Keeratichananont S, Sobhonslidsuk A, Kitiyakara T. et al. The role of liquid simethicone in enhancing endoscopic visibility prior to esophagogastroduodenoscopy (EGD): A prospective, randomized, double-blinded, placebo-controlled trial. J Med Assoc Thail 2010; 93: 892-897
• 8 Brecevic L, Bosan-Kilibarda I, Strajnar F. Mechanism of antifoaming action of simethicone. J Appl Toxicol JAT 1994; 14: 207-211
• 9 Chang C-C, Chen S-H, Lin C-P. et al. Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. World J Gastroenterol 2007; 13: 444-447
• 10 Asl SMKH, Sivandzadeh GR. Efficacy of premedication with activated Dimethicone or N-acetylcysteine in improving visibility during upper endoscopy. World J Gastroenterol WJG 2011; 17: 4213-4217
• 11 Uedo N, Yao K. Endoluminal diagnosis of early gastric cancer and its precursors: bridging the gap between endoscopy and pathology. Adv Exp Med Biol 2016; 908: 293-316
• 12 Cho YK. How to improve the quality of screening endoscopy in korea: national endoscopy quality improvement program. Clin Endosc 2016; 49: 312-317
• 13 Bisschops R, Areia M, Coron E. et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2016; 48: 843-864
• 14 Chang W-K, Yeh M-K, Hsu H-C. et al. Efficacy of simethicone and N-acetylcysteine as premedication in improving visibility during upper endoscopy. J Gastroenterol Hepatol 2014; 29: 769-774
• 15 Bertoni G, Gumina C, Conigliaro R. et al. Randomized placebo-controlled trial of oral liquid simethicone prior to upper gastrointestinal endoscopy. Endoscopy 1992; 24: 268-270
• 16 McNally MPR, Maydonovitch CL, Wong CRKH. The effectiveness of simethicone in improving visibility during colonoscopy: a double-blind randomized study. Gastrointest Endosc 1988; 34: 255-258
• 17 Veitch AM, Uedo N, Yao K. et al. Optimizing early upper gastrointestinal cancer detection at endoscopy. Nat Rev Gastroenterol Hepatol 2015; 12: 660-667
• 18 Bhandari P, Green S, Hamanaka H. et al. Use of Gascon and Pronase either as a pre-endoscopic drink or as targeted endoscopic flushes to improve visibility during gastroscopy: a prospective, randomized, controlled, blinded trial. Scand J Gastroenterol 2010; 45: 357-361
• 19 Woo JG, Kim TO, Kim HJ. et al. Determination of the optimal time for premedication with pronase, dimethylpolysiloxane, and sodium bicarbonate for upper gastrointestinal endoscopy. J Clin Gastroenterol 2013; 47: 389-392
• 20 Monrroy H, Vargas JI, Glasinovic E. et al. Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial. Gastrointest Endosc 2018; 87: 986-993